Regeneron Pharmaceuticals (REGN) Non-cash Items (2009 - 2026)

Regeneron Pharmaceuticals' Non-cash Items history runs 18 years deep, the most recent figure standing at $351.7 million for Q1 2026.

• On a quarterly basis, Non-cash Items rose 48.77% year-over-year to $351.7 million in Q1 2026; TTM through Mar 2026 was $589.3 million, a 207.89% increase from a year earlier, with the FY2025 full-year figure at $474.0 million, up 5900.0% from the prior year.
• Non-cash Items climbed to $351.7 million in Q1 2026 per REGN's latest filing, from $326.1 million in the prior quarter.
• Across five years, Non-cash Items topped out at $1.1 billion in Q1 2022 and bottomed at -$1.1 billion in Q2 2024.
• The 5-year median for Non-cash Items is $158.7 million (2025), against an average of $126.5 million.
• Biggest YoY gain for Non-cash Items was 593.71% in 2024; the steepest drop was 2096.85% in 2024.
• Year by year, Non-cash Items stood at $522.8 million in 2022, then slumped by 113.37% to -$69.9 million in 2023, then surged by 593.71% to $345.1 million in 2024, then decreased by 5.51% to $326.1 million in 2025, then advanced by 7.85% to $351.7 million in 2026.
• Per Business Quant, the three latest REGN Non-cash Items figures stand at $351.7 million (Q1 2026), $326.1 million (Q4 2025), and $158.7 million (Q3 2025).